Focusing on Whole-Cycle Diabetes Management: Sinocare’s Digital Solutions Spotlight Core Clinical Challenges at CDS 2025

From November 19–22, 2025, the 2025 Annual Meeting of the Chinese Diabetes Society (CDS) was held in Xi’an. Sinocare Inc., a global leader in digital diabetes management and chronic disease diagnostics, showcased its comprehensive digital solutions at the conference. A central question sparked widespread discussion among experts: “Despite the rising number of antidiabetic medications, why do diabetes awareness, treatment, and control rates still fall short of expectations?” Experts agreed that effective diabetes management requires more than blood glucose control—it demands a patient-centered approach and a digitally enabled, whole-cycle health management ecosystem.

Digitalization Becomes an Industry Consensus: Expert Forum Sets the Direction for Future Development

During the conference, Professors Weng Jianping and Li Qifu co-chaired the symposium “Progress in Digital Diabetes Management Research,” providing clear guidance for the digital transformation of the industry. Prof. Zheng Xueying of the First Affiliated Hospital of the University of Science and Technology of China presented insights from China’s first Guideline on Intelligent Digital Management of Type 1 Diabetes, establishing a standardized framework for clinical practice. Prof. Zhou Jian of Shanghai Sixth People’s Hospital shared findings from the CONVERT study, highlighting the value of real-time continuous glucose monitoring (CGM) in non-insulin-treated type 2 diabetes. Prof. Jin Ping of Xiangya Third Hospital, Central South University, conducted an in-depth analysis of CGM accuracy in ICU critical-care settings. Experts repeatedly emphasized the same direction: continuous data, coordinated services, and proactive management are the new paradigm for diabetes care.

Addressing Three Core Clinical Pain Points: Sinocare’s Digital Solutions Offer Practical Answers

With “Digital-Driven, Whole-Process Protection” as its core philosophy, Sinocare introduced a comprehensive system of digital solutions covering in-hospital care, out-of-hospital follow-up, and hierarchical medical services.

1. Solving the “Clinical Information Island” Problem: Enabling Cross-Department Hospital-Wide Glycemic Management

Non-endocrinology inpatients often experience delayed intervention due to lack of collaborative workflows. Sinocare’s Hospital-Wide Glycemic Management System, integrated with devices such as the ZhenZhun 8000 blood glucose meter, enables: automatic cross-department consultation requests,  a virtual “multi-disciplinary ward”, remote standardized treatment planning by endocrinologists. This model shifts hospital diabetes care from “single-department management” to “hospital-wide coordination.”

2. Bridging the “Follow-Up Gap” After Discharge: Extending Glycemic Control Beyond the Hospital

Patients commonly face a management vacuum after leaving the hospital. With Sinocare’s Out-of-Hospital Health Management System, physicians can: access real-time data from the iCan CGM, conduct trend analysis, deliver proactive remote intervention. This transforms traditional, passive outpatient visits into data-driven, continuous care.

3. Overcoming Hierarchical Care Barriers: Empowering Primary Healthcare Institutions

Primary care screening often fails to align with specialist treatment due to insufficient integration.

The Integrated Medical–Preventive Chronic Disease Management System provides: intelligent referral-pathway recommendations, risk assessment tools, a coordinated, multi-level healthcare network. This opens the “last mile” of hierarchical diabetes management.

Full-Spectrum Product Ecosystem Strengthens the Foundation of Digital Care

To support whole-cycle digital management, Sinocare has built a comprehensive product matrix covering every stage of diabetes care.

Blood Glucose Monitoring Systems (BGM): ZhenZhun 2000, ZhenZhun 3000, KA-11 blood glucose & ketone meter; Continuous Glucose Monitoring (CGM): Sinocare iCan CGM serves as the data hub connecting hospital and home; Multi-Indicator Testing: Cr1 Air creatinine analyzer, H102 Air hemoglobin analyzer. These devices help hospitals perform early screening and risk management for diabetes complications.

From Numbers to Daily Life: Sinocare’s Mission in Whole-Cycle Diabetes Care

Diabetes management is not merely about controlling glucose values—it requires understanding and supporting patients across every daily life scenario. Sinocare firmly believes that only when technology is deeply integrated into clinical pathways can the mission be fulfilled:

“To provide innovative, high-quality products and services to people with diabetes and related chronic diseases worldwide, helping them improve their quality of life.”

From breaking the monopoly with the first domestically produced glucose meter to today’s full ecosystem covering in-hospital treatment, home-based management, and primary-care screening, Sinocare’s development has always been aligned with China’s national agenda for chronic disease control.

Its hospital-wide glycemic management system and iCan CGM—highlighted at CDS 2025—now serve over 4,000 hospitals and tens of millions of patients across China.

Looking ahead, Sinocare will continue to strengthen its digital innovation capabilities and accelerate the translation of scientific research into practical clinical solutions. Riding the wave of digital transformation in diabetes care, Sinocare is not only pioneering scalable models for the industry but also contributing meaningfully to the advancement of Healthy China.